Scholars@Duke

An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC).

Conferences
Halabi, S; Ou, S; Vogelzang, NJ; Small, EJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 20, 2006
Link to item

Duke Scholars

Susan Halabi
Author Susan Halabi Biostatistics & Bioinformatics, Division of Biostatistics
Altmetric Attention Stats
Dimensions Citation Stats

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

June 20, 2006

Volume

24

Issue

18

Start / End Page

230S / 230S

Location

Atlanta, GA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Halabi, S., Ou, S., Vogelzang, N. J., & Small, E. J. (2006). An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 24, pp. 230S-230S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY.
Halabi, S., S. Ou, N. J. Vogelzang, and E. J. Small. “An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC).” In JOURNAL OF CLINICAL ONCOLOGY, 24:230S-230S. AMER SOC CLINICAL ONCOLOGY, 2006.
Halabi S, Ou S, Vogelzang NJ, Small EJ. An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 230S-230S.
Halabi, S., et al. “An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 18, AMER SOC CLINICAL ONCOLOGY, 2006, pp. 230S-230S.
Halabi S, Ou S, Vogelzang NJ, Small EJ. An elevated body mass (BMI) index predicts far better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 230S-230S.

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

June 20, 2006

Volume

24

Issue

18

Start / End Page

230S / 230S

Location

Atlanta, GA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis